We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current AKTX market cap is 42.79M. The company's latest EPS is USD -0.6151 and P/E is -2.16.
| Quarter End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.33M | -1.46M | -5.9M | -5.24M | -5.82M |
| Net Income | -4.35M | -1.45M | -5.79M | -5.18M | -5.68M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 556k | 0 | 0 | 330k | 0 |
| Operating Income | -17.45M | -17.24M | -25.4M | -19.73M | -21.64M |
| Net Income | -17.08M | -17.42M | -17.01M | -12.24M | -19.79M |
| Quarter End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 4.83M | 14.72M | 11.65M | 19.46M | 11.37M |
| Total Liabilities | 3.24M | 3.36M | 6.09M | 5.52M | 3.05M |
| Total Equity | 1.59M | 11.36M | 5.56M | 13.93M | 8.33M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 14.61M | 11.65M | 16.22M | 5.57M | 50.56M |
| Total Liabilities | 5.22M | 6.09M | 10.98M | 4.58M | 28.33M |
| Total Equity | 9.38M | 5.56M | 5.24M | 988k | 22.23M |
| Quarter End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -12.28M | -13.84M | N/A | -5.05M | -13.62M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 1.99M | 13.18M | N/A | 12.37M | 12.37M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -16.95M | -18.85M | -21.5M | -16.38M | N/A |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 25.07M | 14.29M | 25.29M | 6.97M | N/A |
| Market Cap | 42.79M |
| Price to Earnings Ratio | -2.16 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 16.46 |
| Price to Book Ratio | 1.93 |
| Dividend Yield | - |
| Shares Outstanding | 32.18M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.18 (12.86%) |
| Company Name | Akari Therapeutics PLC |
| Address |
highdown house yeoman west sussex BN99 3HH |
| Website | https://www.akaritx.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
